Back to top
more

Akero Therapeutics (AKRO)

(Delayed Data from NSDQ)

$29.63 USD

29.63
281,767

+0.55 (1.89%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $29.63 0.00 (0.00%) 4:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Reata (RETA) Announces FDA's Acceptance of Skyclarys PAS

by Zacks Equity Research

Reata (RETA) gets FDA acceptance for the filing of new drug application supplement approval for Skyclarys' release.

GSK Announces Extension of FDA Review for Rare Blood Therapy

by Zacks Equity Research

GSK announces the FDA's extension of the review period of its new drug application for momelotinib to treat myelofibrosis by three months. A decision is now expected on Sep 16, 2023.

Aldeyra (ALDX) Up On Positive Data From Conjunctivitis Study

by Zacks Equity Research

Aldeyra (ALDX) soars on meeting primary and secondary endpoints in the late-stage study of reproxalap for patients with allergic conjunctivitis.

Iovance (IOVA) Updates on Combo Drug in Advanced Melanoma Study

by Zacks Equity Research

Iovance (IOVA) announces randomizing the first patient in the TILVANCE-301 study evaluating the safety and efficacy of its lifileucel/Keytruda combo therapy in frontline advanced melanoma patients.

Lava (LVTX) Discontinues Hematological Tumor Study, Shares Fall

by Zacks Equity Research

Lava (LVTX) falls 10% due to its decision to discontinue the study on LAVA-051, which is being evaluated for multiple hematological tumors. The company shifts focus to LAVA-1207 in the prostate cancer study.

Blue Water (BWV) Up on Acquisition of 6 FDA-Approved Drugs

by Zacks Equity Research

Blue Water (BWV) soars 62% after declaring its deal to purchase six FDA-approved products for $8.5 million. The agreement will help expand the company's portfolio into cardiology and pain management.

IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study

by Zacks Equity Research

IO Biotech (IOBT) falls 25% despite achieving the clinical milestone of enrolling 225 patients in the advanced melanoma study evaluating the IO102-IO103/Keytruda combo.

Can-Fite (CANF) Up on Namodenoson Progress in Pancreatic Cancer

by Zacks Equity Research

Can-Fite's (CANF) shares rise 11.4% as it reveals its plans of submitting an investigational new drug application. The idea is to initiate expansion studies for namodenoson to treat pancreatic carcinoma.

Recursion (RXRX) Up on Completing REC-994 Study Enrollment

by Zacks Equity Research

Recursion's (RXRX) shares rise as it completes patient enrollment for a mid-stage study of REC-994 to treat cerebral cavernous malformations.

Gracell Biotechnologies (GRCL) Surges 62% in a Week: Here's Why

by Zacks Equity Research

Shares of Gracell (GRCL) increase after it reported positive data from two clinical studies, which evaluated its experimental CAR T cell therapy drug in patients with B-cell non-hodgkin's lymphoma and multiple myeloma.

First Wave (FWBI) Surges 33% on Finishing Enrolment in CF Study

by Zacks Equity Research

First Wave (FWBI) completes enrolment in a mid-stage study evaluating its investigational oral capsule in patients with cystic fibrosis. Topline data from the study is expected next month.

Acadia (ACAD) to Begin Study on ACP-101 for Hyperphagia in PWS

by Zacks Equity Research

Acadia (ACAD) is set to begin a pivotal study evaluating a new developmental candidate, ACP-101, in the treatment of hyperphagia associated with Prader-Willi syndrome.

AstraZeneca (AZN) Breast Cancer Combo Drug Gets Priority Review

by Zacks Equity Research

The FDA grants priority review status to AstraZeneca's (AZN) capivasertib/Faslodex combination for the treatment of adult patients with HR-positive, HER2-negative locally advanced breast cancer.

Is Akero Therapeutics (AKRO) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Akero Therapeutics, Inc. (AKRO) and Accelerate Diagnostics (AXDX) have performed compared to their sector so far this year.

Ironwood (IRWD), AbbVie Get FDA Nod for Linzess Label Expansion

by Zacks Equity Research

Ironwood (IRWD) lead drug Linzess gets FDA approval for pediatric functional constipation The label expansion of the drug is expected to boost the company's sales.

Intellia (NTLA) Up on Positive Data Updates From HAE Study

by Zacks Equity Research

Intellia's (NTLA) promising interim data on the early-stage study of NTLA-2002 shows potential as a single-dose treatment for hereditary angioedema.

Editas (EDIT) Posts Upbeat Initial Data From SCD & TDT Studies

by Zacks Equity Research

Editas (EDIT) announces positive preliminary safety and efficacy data from patients treated with its lead drug, EDIT-301, in the RUBY and EdiTHAL studies to treat SCD and TDT, respectively.

AstraZeneca (AZN) & Quell to Co-Develop Autoimmune Cell Therapies

by Zacks Equity Research

AstraZeneca (AZN) enters into a collaboration agreement with Quell Therapeutics to co-develop novel cell therapy options in major autoimmune indications for an upfront payment of $85 million.

Rocket (RCKT) Heart Disease Drug Gets Fast Track & Orphan Drug Tag

by Zacks Equity Research

The FDA grants fast track tag and orphan drug designation to Rocket's (RCKT) investigational gene therapy candidate, RP-A601, for cardiac indication. The stock gains 2.3% following the news.

Timber (TMBR) Surges on Carcinogenicity Waiver for TMB-001

by Zacks Equity Research

Timber (TMBR) receives a dermal carcinogenicity waiver from the FDA for TMB-001, which is being developed to treat moderate-to-severe subtypes of congenital ichthyosis.

AVITA (RCEL) Gets FDA Nod for Expanded Use of RECELL System

by Zacks Equity Research

AVITA (RCEL) surges on FDA approval for expanded use of its RECELL System to treat full-thickness skin defects.

Alkermes (ALKS) Gets Final Award in Janssen Arbitration, Ups View

by Zacks Equity Research

Alkermes (ALKS) receives final award in arbitration proceedings with partner Janssen. It also raises its financial outlook for 2023.

Akero Therapeutics, Inc. (AKRO) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

Akero Therapeutics, Inc. (AKRO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Bellerophon (BLPH) Down 87% as Lung Disease Candidate Fails

by Zacks Equity Research

Bellerophon's (BLPH) shares fall as a late-stage study of INOpulse to treat fibrotic interstitial lung disease fails to meet its primary endpoint.

Ultragenyx (RARE) Posts Data From Osteogenesis Imperfecta Study

by Zacks Equity Research

Ultragenyx (RARE), along with partner Mereo BioPharma, announces encouraging data on mid-stage study evaluating setrusumab for patients with osteogenesis imperfecta.